| Literature DB >> 15165929 |
Alawi A Alsheikh-Ali1, Richard H Karas.
Abstract
On the basis of adverse events reported to the US Food and Drug Administration, it was observed that atorvastatin-associated adverse event reports were 3.1 times more likely to list rosiglitazone or pioglitazone as a concomitant medication compared with simvastatin-associated adverse event reports.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15165929 DOI： 10.1016/j.amjcard.2004.02.045
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778